In a strategic move beyond liver-focused therapies, Intellia Therapeutics and Regeneron Pharmaceuticals have announced the expansion of their CRISPR collaboration. Following their 2016 partnership, the two companies achieved a milestone in 2021 with first-in-human gene editing results.
This expanded collaboration aims to develop in vivo CRISPR-based therapies for neurological and muscular diseases. Regeneron will contribute its proprietary adeno-associated virus vectors, while Intellia will bring its Nme2 CRISPR/Cas9 systems adapted for viral vector delivery.
Unlike traditional partnerships, no upfront payments are involved. Instead, the companies will focus on two in vivo non-liver targets initially. Intellia will lead the editing methodology, and Regeneron will handle targeted viral vector delivery.
Each company will independently lead development and commercialization for one target, with an option for the other to join in a 50/50 co-development and co-commercialization agreement. The collaboration, which began in 2016, has undergone revisions, with the latest extension until April 2024.
Their groundbreaking achievement so far includes the in vivo CRISPR/Cas9 genome editing candidate NTLA-2001 for transthyretin amyloidosis, demonstrating a reduction of serum levels of transthyretin, a key biomarkers for the disease. As Intellia and Regeneron pioneer CRISPR-based therapies beyond the liver, the scientific community anticipates potential breakthroughs in treating neurological and muscular diseases.
Check out our AAV CDMO service to expedite your gene therapy research
PackGene is a CRO & CDMO technology company that specializes in packaging recombinant adeno-associated virus (rAAV) vectors. Since its establishment in 2014, PackGene has been a leader in the AAV vector CRO service field, providing tens of thousands of custom batches of AAV samples to customers in over 20 countries. PackGene offers a one-stop CMC solution for the early development, pre-clinical development, clinical trials, and drug approval of rAAV vector drugs for cell and gene therapy (CGT) companies that is fast, cost-effective, high-quality, and scalable. Additionally, the company provides compliant services for the GMP-scale production of AAVs and plasmids for pharmaceutical companies, utilizing five technology platforms, including the π-Alpha™ 293 cell AAV high-yield platform and the π-Omega™ plasmid high-yield platform. PackGene’s mission is to make gene therapy affordable and accelerate the launch of innovative gene drugs. The company aims to simplify the challenging aspects of gene therapy development and industrialization processes and provide stable, efficient, and economical rAAV Fast Services to accelerate gene and cell therapy development efforts from discovery phase to commercialization.
Related News
Exploring Tau Protein’s Role in Glaucoma: New Insights and Therapeutic Potential
Glaucoma, a chronic neurodegenerative disorder, leads to irreversible vision loss by damaging retinal ganglion cells (RGCs) and the optic nerve, often associated with increased intraocular pressure (IOP). Despite the benefits of IOP-lowering treatments, the underlying...
FDA-mandated CAR-T monitoring period could be halved, say researchers
In patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCL), the two hallmark post-chimeric antigen receptor (CAR)-T therapy toxicities are extremely rare after two weeks, supporting a shorter, more flexible toxicity monitoring period, according to a study...
Ancestral CRISPR-Cas13 Ribonucleases Discovered: Implications for Genome Editing
In a pioneering study published in *Science*, a team of researchers led by Peter H. Yoon and Jennifer A. Doudna from the University of California, Berkeley, has made a remarkable discovery in the realm of CRISPR technology. The team has identified an ancestral clade...
KBI Biopharma Expands Manufacturing Contract with Global Pharmaceutical Company
KBI Biopharma Inc., a JSR Life Sciences company and global cGMP contract development and manufacturing organization (CDMO), has extended and expanded its manufacturing contract with a leading global pharmaceutical company. Originally initiated in 2020, the renewed...
Related Services
Plasmids GMP Services
Multiple scales & grade of solutions of various kind of plasmids suitable for multiple treatments in a fast and cost effective way.
READ MORE
AAV GMP Services
Ranging from small-scale AAV production, to large-scale AAV cGMP manufacturing for animal studies.
READ MORE
Technology Platforms
PackGene’s proprietary π-Alpha™ 293 AAV High-yield Platform increases AAV production by 3 to 8 times that of traditional platforms.
READ MORE
